Kent Mouw
Radiation Oncology · Boston, MANPI 1407176084
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,245 of the $16,049 with a category attached, or 70.1%. 8 manufacturers reported payments, led by Urogen Pharma, Inc. at 39.9% of the total. Among radiation oncology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 15 payments — averaging $1069.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urogen Pharma, Inc.$6K
- Pfizer$5K
- Astellas Pharma Global Development$3K
- Sanofi$668
- Genentech USA, Inc.$154
- Exelixis Inc.$153
- plus $256 from 2 others
Across 4 payments — averaging $73,768 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$200K
- EMD Serono Research & Development Institute, Inc.$95K
What the payments were for
- Consulting fees$11,24570%
- Speaking & faculty fees$3,50022%
- Travel & lodging$4143%
- Food & beverage$8906%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urogen Pharma, Inc. | 1 | $6,400 |
| Pfizer | 4 | $5,073 |
| Astellas Pharma Global Development | 1 | $3,345 |
| Sanofi | 4 | $668 |
| Genentech USA, Inc. | 1 | $154 |
| Exelixis Inc. | 2 | $153 |
| Medtronic | 1 | $145 |
| Merck | 1 | $111 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JELMYTO$6,400
- PADCEV$3,345
- NO PRODUCT DISCUSSED$573
- Cabometyx$127
- KEYTRUDA$111
How this compares
$16,049 in reported general payments places this provider in the 90th percentile of 200 radiation oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 25 | $689 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Boston
- Peter OrioBoston$1.8M
- Paul NguyenBoston$721K
- Jason EfstathiouBoston$156K
- Jonathan SchoenfeldBoston$53K
- Martin KingBoston$37K
- Raymond MakBoston$36K
- Shannon MacdonaldBoston$33K
- Nima AghdamBoston$29K
- Rachel JimenezBoston$28K
- Theodore HongBoston$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.